Sun Pharma Q4 Results: Firm returns to black, posts cons PAT of Rs 1,984 cr, declares Rs 4/share dividend

The pharma major reported a profit of Rs 2,166.01 crore in Q3FY23.

The revenue for the reporting quarter stood at Rs 10,725.57 crore which was up over 12% year-on-year (YoY) versus Rs 9,560.35 crore in Q4FY22.

The company also approved a final dividend of Rs 4 per equity share which will be subject to the approval of the shareholders.

Post Q4 earnings announcement, the company’s stock rose 3% to trade at Rs 973 on BSE.

The net profit for FY23 stood at Rs 8,473.58 crore as compared to Rs 3,272.73 crore in FY22, rising nearly 160% YoY.

Gross sales stood at Rs 43,278.9 crore for FY23, rising 12.6% over same period last year, the company said in its filing to exchanges. India formulation sales were at Rs 13,603.10 crore, up 6.6% over same period last year.Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 11,646.80 crore, up 12% over same period last year. EBITDA margin for FY23 stood at 26.5% as compared to 26.9% for same period last year.